Form D · Biotechnology
BioNTech SE
Mainz, 2M · CIK 0001776985
Offering snapshot reported Apr 14, 2022 · SEC filing
- Reported sold
- $150M Offering amount: $150M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Apr 11, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 14, 2022 | Initial | $149,999,985 | No comparison | 1 | SEC filing |
| Sep 17, 2020 | Initial | $250,000,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-441822
Source: Form D, filed Apr 14, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jens Holstein | Executive |
| Christoph Huber | Director |
| Helmut Jeggle | Director |
| Sean Marett | Executive |
| Michael Motschmann | Director |
| Sierk Poetting | Executive |
| Ryan Richardson | Executive |
| Ugur Sahin | Executive |
| Ozlem Tureci | Executive |
| Ulrich Wandschneider | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
An Der Goldgrube 12
Mainz, 2M, D-55131
Mainz, 2M, D-55131